Protein lost in lung cancer reveals hidden layer of gene control
Scientists at Barts Cancer Institute, Queen Mary University of London, have uncovered an important way that cells keep their genes under control. The discovery could help explain one of the earliest […]
First patient in world given pioneering cancer vaccine at Clatterbridge
A patient at Clatterbridge is the first person in the world to be given a pioneering cancer vaccine for the most common type of lung cancer. Clinicians and researchers at […]
Scientists uncover promising new way to treat an ‘undruggable’ type of lung cancer
Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for thousands of patients with lung cancer driven by a rare type of […]
Charity launches patient guide for rare type of non-smoking lung cancer
ALK Positive UK has today launched its new guide to help people diagnosed with ALK-positive lung cancer to ask the right questions of their healthcare professionals during medical consultations.1 ALK-positive […]
Antibody may improve treatment response in lung cancer
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumours in preclinical models of non-small cell lung cancer (NSCLC), even those resistant to a targeted therapy, […]
Urine test could help detect lung cancer years before symptoms occur
Cambridge scientists hunting tell-tale killer ‘zombie’ cells that signal early lung cancer have developed a world-first urine test that could transform diagnosis and survival for thousands of patients. As published […]
Scientists discover how lung cancer spreads in its later stages
Researchers at UCL and University College London Hospitals NHS Foundation Trust, working with colleagues at the Francis Crick Institute, have discovered how lung cancer spreads in the final stages of […]
RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib) is accepted for use within NHS Scotland as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations
Johnson & Johnson welcomes the decision made today by the Scottish Medicines Consortium (SMC) to accept RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib), for use within the National Health Service (NHS) Scotland […]
NICE issues Final Draft Guidance recommending that RYBREVANT®▼(amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adult
Johnson & Johnson is pleased to announce today that the National Institute for Health and Care Excellence (NICE) has recommended that RYBREVANT®▼ (amivantamab) with carboplatin and pemetrexed can be used […]
NHS first as Barts patient treated with new surgical robot
A patient at Barts Health NHS Trust is the first in the NHS to have lung cancer surgery using the newest robotic surgical technology. The operation was carried out at […]
